Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Franz-Adolph Hoffmann"'
Autor:
Franz-Adolph Hoffmann, Cornelia Becker, H. K. Al-Ali, D. Langanke, Dietger Niederwieser, U. von Gruenhagen
Publikováno v:
Journal of Clinical Oncology. 28:1141-1141
1141 Background: Metastatic BC is still an incurable disease with poor long-term PFS. Previous studies using allogeneic SCT were performed in patients with advanced metastatic disease irrespective of the response at the time of SCT. In this study we
Autor:
Ursula Haak, Rita Pasold, Sabine Hahnfels, Thomas-Hein Ittel, Christian Klinkenstein, Sabine Neser, Andreas Neubauer, Franz-Adolph Hoffmann, Ullrich von Gruenhagen, Ullrich Mey, Klaus Dachselt, Dorothee Bleyl, Mathias Freund, Ralph Naumann, Klaus Hieke, Heiner Wolf, Erika Kettner, Thomas Fietz, Volker Lakner, Helga Schwenke, Gottfried Doelken, Detlev Haehling, Henning Eschenburg, Klaus Hoeffken, Michael Assmann, Dietger Niederwieser, Michael Herold, Astrid Franke, Norbert Grobe, Robert Rohrberg, Michael R. Clemens, H.-H. Wolf, Peter Richter
Publikováno v:
Blood. 104:87-87
Background: Clinical superiority of R-MCP (rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP alone in patients with advanced stage indolent Non-Hodgkin’s-Lymphoma was demonstrated in a prospective, randomized, controlled, multicenter cli
Autor:
Ursula Haak, Astrid Franke, Ullrich Mey, Peter Richter, Rita Pasold, Stefanie Srock, Volker Lakner, Franz-Adolph Hoffmann, Sabine Neser, Gottfried Dölken, Thomas Ittel, Helga Schwenke, Ralph Naumann, Thomas Fietz, Andreas Neubauer, Michael Herold, Robert Rohrberg, Erika Kettner, Norbert Grobe, Mathias Freund, Dietger Niederwieser, Michael Assmann, Christian Klinkenstein, Dorothee Bleyl, Heiner Wolf, Detlev Hähling, Ullrich von Gruenhagen, Michael R. Clemens, H.-H. Wolf, Klaus Dachselt, Sabine Hahnfeld, Henning Eschenburg, Klaus Hoeffken
Publikováno v:
Blood. 104:584-584
Rituximab proved to be effective in relapsed and refractory indolent NHL as a single agent and generated impressive results in phase II studies in combination with chemotherapy. In a prospective randomized trial we compared the efficacy and toxicity